僵直性脊椎炎市場規模、佔有率和成長分析（按藥物類別、分銷管道和地區）- 產業預測 2025-2032

2023 年全球僵直性脊椎炎市場規模價值 67.8 億美元，預計將從 2024 年的 72.8 億美元成長到 2032 年的 128.9 億美元，預測期內（2025-2032 年）的複合年成長率為 7.4%。

僵直性脊椎炎的特徵是脊椎和關節的慢性炎症，全球僵直性脊椎炎市場呈現成長趨勢，這得益於全球盛行率和認知度的上升。診斷方法的改進使得早期發現成為可能，有助於改善治療效果。醫學研究的重大發展促成了非類固醇消炎劑、TNF抑制劑和白細胞介素抑制劑等創新治療方法的推出，這些治療方法顯著改善了患者的生活品質並推動了市場需求。人口老化，尤其是受影響更頻繁的男性，進一步加劇了這種成長。然而，市場面臨著諸如由於症狀不明顯而導致的診斷不足、生物製藥成本上升以及某些地區獲得醫療保健的機會有限等挑戰。此外，由於缺乏永久的治療方法，因此需要持續的疾病管理，從而影響未來的市場動態。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 資料和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

僵直性脊椎炎市場規模（依藥物類別及複合年成長率） （2025-2032）

• 市場概況
• 非類固醇消炎劑(NSAID)
• TNF 抑制劑
  • Humira
  • Simponi
  • Remicade
  • Enbrel
  • Cimzia
  • 其他 TNF 抑制劑
• 其他藥物類別

僵直性脊椎炎市場規模（依分銷管道和複合年成長率） (2025-2032)

• 市場概況
• 醫院藥房
• 零售藥局
• 其他

僵直性脊椎炎市場規模（按地區）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分析市場佔有率
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• AbbVie Inc.（United States）
• Amgen Inc.（United States）
• Pfizer Inc.（United States）
• Johnson & Johnson（United States）
• Novartis AG（Switzerland）
• UCB SA（Belgium）
• Eli Lilly and Company（United States）
• Merck & Co., Inc.（United States）
• Boehringer Ingelheim International GmbH（Germany）
• Gilead Sciences Inc.（United States）
• Bristol-Myers Squibb Company（United States）
• AstraZeneca plc（United Kingdom）
• Sanofi SA（France）
• GlaxoSmithKline plc（United Kingdom）
• Horizon Therapeutics plc（Ireland）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Sandoz International GmbH（Germany）
• Zydus Lifesciences Limited（India）
• Izana Bioscience（United Kingdom）

結論和建議

Global Ankylosing Spondylitis Market size was valued at USD 6.78 billion in 2023 and is poised to grow from USD 7.28 billion in 2024 to USD 12.89 billion by 2032, growing at a CAGR of 7.4% during the forecast period (2025-2032).

The global ankylosing spondylitis market, characterized by chronic spinal and joint inflammation, is on a growth trajectory, propelled by rising global prevalence and awareness. Enhanced diagnostic methods enable early detection, contributing to improved treatment outcomes. Key developments in medical research have introduced innovative therapies, including NSAIDs, TNF inhibitors, and interleukin inhibitors, significantly enhancing patient quality of life and amplifying market demand. The aging population, particularly men who are more frequently affected, further fuels this growth. However, the market faces challenges such as underdiagnosis due to ambiguous symptoms, high costs of biologic therapies, and limited healthcare access in certain regions. Additionally, the absence of a permanent cure necessitates ongoing disease management, shaping the future dynamics of the market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Ankylosing Spondylitis market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Ankylosing Spondylitis Market Segments Analysis

Global Ankylosing Spondylitis Market is segmented by Drug Class, Distribution Channel and region. Based on Drug Class, the market is segmented into Non-Steroidal Anti Inflammatory Drug (NSAID), TNF Inhibitors and Other Drug Classes. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Ankylosing Spondylitis Market

Recent progress in medical research has enhanced our comprehension of ankylosing spondylitis, including its root causes and possible treatment options. The introduction of targeted therapies, particularly tumor necrosis factor (TNF) inhibitors and interleukin inhibitors, has notably transformed the management of this condition. The accessibility of effective medications, alongside the continuous refinement of treatment guidelines, plays a crucial role in driving the expansion of the global ankylosing spondylitis market. With ongoing advancements in therapeutic strategies and an increasing awareness of the disease, the market is poised for significant growth, addressing the unmet needs of individuals affected by this condition.

Restraints in the Global Ankylosing Spondylitis Market

The global ankylosing spondylitis market faces significant constraints due to the necessity of long-term disease management and ongoing treatment. Effective control of this condition hinges on patients' compliance with medication schedules, commitment to lifestyle changes, and regular medical follow-ups. These factors can pose challenges to consistent patient adherence and effective disease monitoring. As a result, the difficulties associated with sustained management of ankylosing spondylitis may hinder overall market growth, as patients struggle to maintain the necessary regimen for optimal health outcomes. Addressing these compliance issues is crucial for unlocking the potential of the ankylosing spondylitis treatment market.

Market Trends of the Global Ankylosing Spondylitis Market

The Global Ankylosing Spondylitis market is witnessing a significant trend towards early diagnosis and treatment, driven by the increasing recognition of the importance of timely intervention in managing this chronic inflammatory condition. Enhanced diagnostic techniques and heightened awareness among healthcare professionals and patients are contributing to an uptick in early detection rates. This proactive approach fosters prompt initiation of therapies aimed at controlling inflammation, alleviating symptoms, and staving off disease progression. Consequently, patient advocacy organizations and healthcare providers are intensifying educational campaigns, thereby shaping a market landscape that prioritizes optimal patient outcomes and drives demand for innovative treatment modalities.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Ankylosing Spondylitis Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Non-Steroidal Anti Inflammatory Drug(NSAID)
• TNF Inhibitors
  • Humira
  • Simponi
  • Remicade
  • Enbrel
  • Cimzia
  • Other TNF Inhibitors
• Other Drug Classes

Global Ankylosing Spondylitis Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Others

Global Ankylosing Spondylitis Market Size & CAGR (2025-2032)

• North America (Drug Class, Distribution Channel)
  • US
  • Canada
• Europe (Drug Class, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• UCB S.A. (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Horizon Therapeutics plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Lifesciences Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Izana Bioscience (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations